HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo
HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo

REMD Biotherapeutics

Ownership
Private
Therapeutic Areas
OncologyInfectious DiseasesEndocrinology
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Monoclonal antibodyBispecific antibodyFusion proteinProtein

REMD Biotherapeutics General Information

Positive top-line Phase 2 results for volagidemab (REMD-477) in type 1 diabetes patients demonstrated safety, efficacy, and pharmacodynamics, supporting advancement to Phase 3. Preclinical proof of concept established for other metabolic and oncology indications[1][5][6].

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Camarillo, California
United States

Drug Pipeline

No pipeline data available

For full access to REMD Biotherapeutics's pipeline data

Book a demo

Key Partnerships

GenScript ProBio

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

REMD Biotherapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view REMD Biotherapeutics's complete valuation and funding history, request access »

REMD Biotherapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals